Intradermal Polynucleotide Injections for Facial Atopic Dermatitis in Adults

A pilot clinical trial evaluating the effectiveness of PN (Rejuran®) for the improvement of facial skin in patients with atopic dermatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0011301

Enrollment

Registered

2025-12-11

Start date

2024-09-06

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Polynucleotide (PN)-containing product (Rejuran®) is intradermally injected across the entire facial area of patients enrolled in the study. A total of three treatment sessions are ad

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A. Male or female patients aged 18 years or older with a diagnosis of atopic dermatitis B. Individuals presenting with facial erythema (flushing or redness) due to atopic dermatitis who seek improvement of this symptom C. Individuals who are able to comply with the clinical trial procedures and scheduled visits D. Individuals who voluntarily provide written informed consent after fully understanding the nature of the study and agree not to undergo any other facial procedures (e.g., fillers, photorejuvenation, chemical peels, or dermabrasion) during the study period

Exclusion criteria

Exclusion criteria: A. Individuals planning to undergo any facial cosmetic procedures during the study period, including filler injections, photorejuvenation, chemical peeling, or mechanical dermabrasion B. Pregnant or breast feeding women C. Individuals with a history of keloid formation D. Individuals with known allergies or hypersensitivity to the investigational product or its components E. Any other individuals deemed inappropriate for participation in the study by the principal investigator, based on medical or clinical judgment

Design outcomes

Primary

Measure	Time frame
Erythema index (EI) is measured using a Mexameter, skin hydration is assessed with a Corneometer, and transepidermal water loss (TEWL) is evaluated using a Tewameter. Skin elasticity is measured using a Cutometer. Additionally, investigator assessments, patient satisfaction scores, and facial imaging with the Mark-Vu diagnostic system are performed.	—

Secondary

Measure	Time frame
IL-1b; IL-18	—

Countries

Korea, Republic of

Contacts

Public ContactKui Young Park

Chung-Ang Univerisity Hospital

kyky@cauhs.or.kr+82-2-6299-1530

Outcome results